Inhibition of trypanothione reductase by substrate analogues

Organic Letters

Volumn 2, Issue 23, 2000, Pages 3639-3642

  Garrard, Elizabeth A ^a   Borman, Emily C ^a   Cook, Brian N ^a   Pike, Emily J ^a   Alberg, David G ^a  

^a CARLETON COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; ENZYME INHIBITOR; GLUTATHIONE REDUCTASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OXIDOREDUCTASE; TRYPANOTHIONE REDUCTASE;

ANIMAL; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; ENZYME SPECIFICITY; ENZYMOLOGY; SYNTHESIS; TRYPANOSOMA;

ANIMALS; ENZYME INHIBITORS; GLUTATHIONE REDUCTASE; INDICATORS AND REAGENTS; NADH, NADPH OXIDOREDUCTASES; NADP; SUBSTRATE SPECIFICITY; TRYPANOSOMA;

EID: 0034676618     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol0065423     Document Type: Article

References (39)

1. Fairlamb, A. H.; Cerami, A. Annu. Rev. Microbiol. 1992, 46, 695-729.
2. Fairlamb, A. H.; Blackburn, P.; Ulrich, P.; Chait, B. T.; Cerami, A. Science 1985, 227, 1485-1487.
3. (a) Walsh, C.; Bradley, M.; Nadeau, K. Trends Biochem. Sci. 1991, 16, 305-309.
4. (b) Walsh, C.; Bradely, M.; Nadeau, K. Curr. Top. Cell. Regul. 1992, 33, 409-417.
5. For leading references, see: (a) Bond, C. S.; Zhang, Y.; Berriman, M.; Cunningham, M. L.; Fairlamb, A. H.; Hunter, W. N. Structure (London) 1999, 7, 81-89.
6. (b) Borges, A.; Cummingham, M. L.; Tovar, J.; Fairlamb, A. H. Eur. J. Biochem. 1995, 228, 745-752.
7. (c) Leichus, B. N.; Bradley, M.; Nadeau, K.; Walsh, C. T.; Blanchard, J. S. Biochemistry 1992, 31, 6414-6420.
8. For leading references, see: (a) Schirmer, R. H.; Krauth-Siegel, R. L.; Schulz, G. E. In Glutathiome: Chemical, Biochemical, and Medicinal Aspects. Part A; Dolphin, D., Poulson, R. Avramovic, O., Eds.; John Wiley and Sons: New York, 1989; pp 553-596.
9. (b) Ghisla, S.; Massey, V. Eur. J. Biochem. 1989, 181, 1-17.
10. (c) Karplus, P. A.; Schulz, G. E. J. Mol. Biol. 1989, 210, 163-180.
11. (d) Sweet, W. L.; Blanchard, J. S. Biochemistry 1991, 30, 8702-8709.
12. (a) Shames, S. L.; Fairlamb, A. H.; Cerami, A.; Walsh, C. T. Biochemistry 1986, 25, 3519-3526.
13. (b) Krauth-Siegel, R. L.; Enders, B.; Henderson, G. B.; Fairlamb, A. H.; Schirmer, R. H. Eur. J. Biochem. 1987, 164, 123-128.
14. (a) Dumas, C.; Ouellette, M.; Tovar, J.; Cunningham, M. L.; Fairlamb, A. H.; Tamar, S.; Olivier, M.; Papadopoulou, B. EMBO J. 1997, 16, 2590-2598.
15. (b) Tovar, J.; Cunningham, M. L.; Smith, A. C.; Croft, S. L.; Fairlamb, A. H. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 5311-5316.
16. (c) Krieger, S.; Schwarz, W.; Ariyanayagam, M. R.; Fairlamb, A. H.; Krauth-Siegel, R. L.; Clayton, C. H. Mol. Microbiol. 2000, 35, 542-552.
17. For reviews, see: (a) Schirmer, R. H.; Muller, J. G.; Krauth-Siegel, R. L. Angew. Chem., Int. Ed. Engl. 1995, 34, 141-154.
18. (b) Krauth-Siegel, R. L.; Schöneck, R. FASEB J. 1995, 9, 1138-1146.
19. (c) Krauth-Siegel, R. L.; Coombs, G. H. Parasitol. Today 1999, 75, 404-409.
20. (d) Austin, S. E.; Khan, M. O. F.; Douglas, K. T. Drug Des. Discovery 1999, 16, 5-23.
21. Henderson, G. B.; Fairlamb, A. H.; Ulrich, P.; Cerami, A. Biochemistry 1987, 26, 3023-3027.
22. El-Waer, A. F.; Smith, K.; McKie, J. H.; Benson, T.; Fairlamb, A. H.; Douglas, K. T. Biochim. Biophys. Acta 1993, 1203, 93-98.
23. El-Waer, A.; Douglas, K. T.; Smith, K.; Fairlamb, A. H. Anal. Biochem. 1991, 198, 212-216.
24. Tromelin, A.; Moutiez, M.; Meziane-Cherif, D.; Aumercier, M.; Tartar, A.; Sergheraert, C. Bioorg. Med. Chem. Lett. 1993, 3, 1971-1976.
25. TR amino acid residue numbering is that of the T. cruzi enzyme.
26. One TR-selective covalent inhibitor was recently reported; see ref 4a.
27. Yuen, C. T.; Garforth, J.; Besheya, T.; Jaouhari, R.; McKie, J. H.; Fairlamb, A. H.; Douglas, K. T. Amino Acids 1999, 17, 175-183.
28. This synthesis was inspired by Jurgens' asymmetric synthesis or a diaminopimelic acid derivative, see: Jurgens, A. R. Tetrahedon Lett. 1992, 33, 4727-4730.
29. CH=CH = 15.6 Hz). No trans isomer was observed in the NMR spectrum of this compound.
30. Schöllkopf, U.; Groth, U.; Deng, C. Angew. Chem., Int. Ed. Engl. 1981, 20, 798-799.
31. PyBrop = bromotripyrrolidinophoshonium hexafluorophosphate. Coste, J.; Frérot, E.; Jouin, P. Tetrahedron Lett. 1991, 32, 1967-1970.
32. PyBop = benzotriazole-1-yloxytrispyrrolidinophosphonium hexafluorophosphate. Coste, J.; Le-Nguyen, D.; Castro, B. Tetrahedron Lett. 1990, 31, 205-208.
33. Our low yield in this normally high-yielding Fmoc deprotection reaction was the result of accidental loss of material during purification.
34. Bodanszky, M. Principles of Peptide Synthesis, 2nd ed.; Springer-Verlag: Berlin, 1993; pp 187-188 and references therein.
35. Murray, R. W. Chem. Rev. 1989, 89, 1187-1201.
36. Sullivan, F. X.; Walsh, C. T. Mol. Biochem. Parisitol. 1991, 44, 145-148.
37. Sullivan, F. X.; Shames, S. L.; Walsh, C. T. Biochemistry 1989, 28, 4986-4992.
38. Bailey, S.; Smith, K.; Fairlamb, A. H.; Hunter, W. H. Eur. J. Biochem. 1993, 213, 67-75.
39. We also attempted to fit the data to the uncompetitive and noncompetitive inhibition models using Cleland's UNCOMP and NCOMP programs. As expected, the data for each inhibitor either failed to fit these models or gave a fit significantly worse than that obtained with the competitive model. Cleland, W. W. Methods Enzymol. 1979, 63, 103-138.